Paper Details

  1. Home
  2. Paper Details

Adjuvant immunotherapy: the sting in the tail.

Author: Chatzimavridou-GrigoriadouViktoria, EggermontAlexander M M, FitzgeraldCheryl T, HighamClaire E, LoriganPaul, TrainerPeter J

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Adjuvant immunotherapy with PD-1 inhibitors for melanoma reduces recurrence risk by 40-50%, but carries a 37% risk of immune-related adverse events, with 10-15% being severe. Endocrine toxicities like thyroid dysfunction (15-20%), hypophysitis (2.2%), and diabetes (1%) are common and can be challenging to manage.
Paper Details　
Original Abstract of the Article :
Adjuvant therapy with PD-1 inhibitors for resected Stage III/IV melanoma reduces the risk of recurrence by 40-50% and is now a standard of care. Immune-related adverse events occurred in approximately 37% of patients in the pivotal trials, 10-15% were severe (grade III-IV). Endocrine toxicities were...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ejca.2020.03.016

データ提供：米国国立医学図書館（NLM）

Adjuvant Immunotherapy: A Double-Edged Sword in Melanoma Treatment

In the field of [oncology], adjuvant immunotherapy has emerged as a promising treatment for melanoma. This review explores the use of PD-1 inhibitors as adjuvant therapy for resected Stage III/IV melanoma, highlighting both its benefits and risks. The review notes that while adjuvant immunotherapy with PD-1 inhibitors can significantly reduce the risk of recurrence, it can also cause a range of immune-related adverse events, some of which can be severe and even irreversible.

Balancing the Benefits and Risks of Immunotherapy

The review emphasizes the need for careful consideration of the potential benefits and risks of adjuvant immunotherapy for melanoma. The significant reduction in recurrence risk must be weighed against the possibility of serious immune-related adverse events.

A Complex Landscape in Melanoma Treatment

This review reminds us that the field of melanoma treatment is constantly evolving. It's like navigating a complex desert landscape, where understanding both the benefits and risks of new treatments is crucial for optimal patient care.

Dr.Camel's Conclusion

This review underscores the complexities of adjuvant immunotherapy for melanoma. While offering significant benefits, it also presents potential risks that must be carefully considered. The findings highlight the importance of ongoing research to optimize the use of immunotherapy and minimize its adverse effects.
Date :
  1. Date Completed 2020-11-09
  2. Date Revised 2023-12-13
Further Info :

Pubmed ID

32388064

DOI: Digital Object Identifier

10.1016/j.ejca.2020.03.016

Related Literature

Article Analysis
・Side Effects of levothyroxine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.